KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

  • End date
    Aug 31, 2023
  • participants needed
  • sponsor
    Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Updated on 26 January 2021


This is a Phase 2, open-label, multi-center, single arm study in subjects with advanced thymic carcinoma after failure of platinum-based combination chemotherapy. Subjects should have documented progressive disease while on platinum-based combination chemotherapy. If subjects discontinued platinum-based therapy due to reasons other than progressive disease, subjects should have completed at least 2 cycles of platinum-based combination chemotherapy before the commencement of documented progressive disease. Subjects will be treated with KN046 5 milligram per kilogram every 2 weeks.

Condition Thymoma, Thymomas, thymic carcinoma
Treatment KN046
Clinical Study IdentifierNCT04469725
SponsorJiangsu Alphamab Biopharmaceuticals Co., Ltd
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Male or female, 18 years
Pathologically confirmed diagnosis of thymic carcinoma
Inoperable or metastatic disease
Had failed at least one regimen containing platinum-based combination chemotherapy for locally advanced unresectable or metastatic disease
Baseline measurable disease

Exclusion Criteria

Thymomas, thymolipoma, germ cell tumors, teratomas, seminomas
Leptomeningeal metastasis or untreated active CNS (central nervous system) metastasis or leptomeningeal metastasis
Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks
Has received other anti-tumor treatment within 4 weeks
Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment
Curative radiation within 3 months of the first dose of trial treatment
Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note